Cancer care is entering a new era where understanding what remains after treatment is becoming increasingly important to how clinicians assess risk of recurrence, monitor disease and make treatment decisions. Molecular residual disease (MRD) testing sits at the center of that evolution, with advances in sensitivity, specificity, and performance pushing the boundaries of what MRD can reveal, expanding its potential role in the future of precision oncology.
Join Gina Costa, PhD, senior director, product development, for Abbott's cancer diagnostics business, Viktor Adalsteinsson, PhD, senior director of the Gerstner Center for Cancer Diagnostics at the Broad Institute of MIT and Harvard, and Dr. Anand Patel, hematologist and oncologist with Ascension Wisconsin, for a forward-looking discussion on the evolving MRD landscape, the innovative technologies driving the field, and the impact these advances may have for patients and healthcare providers.
The panel will explore the evolution of MRD and how the next-generation Oncodetect® test reflects where the field is headed; the science behind MAESTRO technology and how tracking more tumor-specific variants creates more opportunities to detect ctDNA when disease burden is exceptionally low; and the physician perspective on translating increasingly sensitive molecular insights into meaningful decisions in practice.
Attendees will gain a clearer understanding of the technologies shaping the next generation of MRD, the opportunities and challenges associated with clinical adoption, and what will be required to move the field from increasingly sophisticated molecular detection toward greater clinical utility and more informed cancer care.